Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis

(2022) Misako Nagasaka et al.   LUNG CANCER

JAK‐STAT core cancer pathway: An integrative cancer interactome analysis

(2022) Fettah Erdogan et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review

(2022) Zizheng Song et al.   Annals of Palliative Medicine

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

(2022) Meredith S. Eno et al.   JOURNAL OF MEDICINAL CHEMISTRY

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer

(2022) Dehua Liao et al.   Frontiers in Pharmacology

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

(2021) Ying Cheng et al.   Targeted Oncology

Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication

(2021) Yuran Qiu et al.   Pharmaceutics

Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations

(2021) Krishna Babu Duggirala et al.   Biomolecules & Therapeutics

Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor–Naive Advanced ALK-Positive Non–Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial

(2021) D. Ross Camidge et al.   Journal of Thoracic Oncology

Lung cancer

(2021) Alesha A Thai et al.   LANCET

Dacomitinib improves chemosensitivity of cisplatin‑resistant human ovarian cancer cells

(2021) Lei Xu et al.   Oncology Letters

Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management

(2021) Liansha Tang et al.   Frontiers in Immunology

Lung Cancer 2020

(2020) Brett C. Bade et al.   CLINICS IN CHEST MEDICINE

Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors

(2020) Dima A. Sabbah et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy

(2020) Wenfeng Fang et al.   Journal of Thoracic Oncology

EGFR activates GDH1 transcription to promote glutamine metabolism through MEK/ERK/ELK1 pathway in glioblastoma

(2020) Rui Yang et al.   ONCOGENE

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

(2020) Jacqueline H. Starrett et al.   CANCER RESEARCH

The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal

(2020) Valerio Gristina et al.   CANCER TREATMENT REVIEWS

Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy

(2020) Yubo Wang et al.   Journal of Thoracic Oncology

Effect of erlotinib combined with cisplatin on IL‑6 and IL‑12 in mice with Lewis lung cancer

(2020) Xu Zhang et al.   Oncology Letters

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations

(2020) Tomomi Masuda et al.   Thoracic Cancer

Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives

(2020) Jingjing Qu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Rab8 and Rabin8-Mediated Tumor Formation by Hyperactivated EGFR Signaling via FGFR Signaling

(2020) Junghwa Choi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Mechanisms of osimertinib resistance and emerging treatment options

(2020) Sabine Schmid et al.   LUNG CANCER

CH7233163 overcomes osimertinib resistant EGFR-Del19/T790M/C797S mutation

(2020) Kenji Kashima et al.   MOLECULAR CANCER THERAPEUTICS

The next tier of EGFR resistance mutations in lung cancer

(2020) Hannah L. Tumbrink et al.   ONCOGENE

Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms

(2020) Mu-Yang Huang et al.   PHARMACOLOGY & THERAPEUTICS

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

(2020) Antonio Passaro et al.   Journal of Thoracic Oncology

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors

(2020) Leilei Wu et al.   Frontiers in Oncology

Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC

(2019) Qun Gao et al.   Journal for ImmunoTherapy of Cancer

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

(2019) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

Case Report: Lung Adenocarcinoma Harboring EGFR-19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy

(2019) Xiaofei Wang et al.   Journal of Thoracic Oncology

On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele specific manner dependent on the original EGFR activating mutation

(2019) Benjamin P Brown et al.   CLINICAL CANCER RESEARCH

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report

(2019) Jing Liu et al.   BMC CANCER

Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation

(2019) Emmanuel Grolleau et al.   Journal of Thoracic Oncology

Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis

(2019) Gang Cheng et al.   Nature Communications

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

(2019) Alessandro Leonetti et al.   BRITISH JOURNAL OF CANCER

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

(2019) Narjust Duma et al.   MAYO CLINIC PROCEEDINGS

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer

(2019) Peter T Harrison et al.   SEMINARS IN CANCER BIOLOGY

Adaptive mutability of colorectal cancers in response to targeted therapies

(2019) Mariangela Russo et al.   SCIENCE

Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs

(2019) Tomomi Sanomachi et al.   Cancers

Advances on Natural Polyphenols as Anticancer Agents for Skin Cancer

(2019) Soraya Sajadimajd et al.   PHARMACOLOGICAL RESEARCH

Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial

(2018) Hiroaki Akamatsu et al.   CANCER SCIENCE

Clinical activity of ASP8273 in Asian patients with non-small cell lung cancer with EGFR activating and T790M mutations

(2018) Haruyasu Murakami et al.   CANCER SCIENCE

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

(2018) Zhe Yang et al.   CLINICAL CANCER RESEARCH

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib

(2018) Qi Zhang et al.   Journal of Thoracic Oncology

Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib

(2018) Yutao Liu et al.   LUNG CANCER

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

(2018) Shang-Gin Wu et al.   Molecular Cancer

Third generation EGFR TKIs: current data and future directions

(2018) Chee-Seng Tan et al.   Molecular Cancer

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

(2018) Chia-Chi Lin et al.   Lancet Respiratory Medicine

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay

(2018) Shinichi Kimura et al.   CANCER SCIENCE

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry

(2018) Xiaoyun Lu et al.   MEDICINAL RESEARCH REVIEWS

Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report

(2018) Jing Zhao et al.   OncoTargets and Therapy

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

(2018) Geoffrey R. Oxnard et al.   JAMA Oncology

Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report

(2018) Yan Zhang et al.   OncoTargets and Therapy

Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M

(2018) Sha Zhao et al.   LUNG CANCER

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance

(2017) Zhen Wang et al.   Journal of Thoracic Oncology

Successful Treatment with Gefitinib in Advanced Non–Small Cell Lung Cancer after Acquired Resistance to Osimertinib

(2017) Nuria Chic et al.   Journal of Thoracic Oncology

Combination Osimertinib and Gefitinib in C797S and T790M EGFR- Mutated Non–Small Cell Lung Cancer

(2017) Surein Arulananda et al.   Journal of Thoracic Oncology

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib

(2017) A. Oztan et al.   LUNG CANCER

Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC

(2017) Franciele H. Knebel et al.   LUNG CANCER

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib

(2017) Sai-Hong Ignatius Ou et al.   LUNG CANCER

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution

(2017) Kaidi Li et al.   ONCOLOGY REPORTS

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

(2017) Ken Uchibori et al.   Nature Communications

EGFR G796D mutation mediates resistance to osimertinib

(2017) Di Zheng et al.   Oncotarget

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

(2017) et al.   Cancers

A Novel EGFR C797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture–Based Next-Generation Sequencing Assay

(2016) Roopika Menon et al.   Journal of Thoracic Oncology

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC

(2016) Melissa Bersanelli et al.   Journal of Thoracic Oncology

S768I Mutation in EGFR in Patients with Lung Cancer

(2016) Konstantinos Leventakos et al.   Journal of Thoracic Oncology

Molecular Docking Optimization in the Context of Multi-Drug Resistant and Sensitive EGFR Mutants

(2016) María García-Godoy et al.   MOLECULES

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

(2016) Yong Jia et al.   NATURE

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

(2016) Xiaoman Li et al.   Oncotarget

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors

(2016) Shuhang Wang et al.   Frontiers of Medicine

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity

(2015) Kenichi Suda et al.   ARCHIVES OF TOXICOLOGY

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

(2015) M. J. Niederst et al.   CLINICAL CANCER RESEARCH

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

(2014) Yuankai Shi et al.   Journal of Thoracic Oncology

EGF receptor trafficking: consequences for signaling and cancer

(2013) Alejandra Tomas et al.   TRENDS IN CELL BIOLOGY

Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization

(2012) Yibing Shan et al.   CELL

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA